MDMAT

MDMAT (or 3,4-Methylenedioxy-N-methylamphetamine) is a psychoactive drug of the substituted amphetamine chemical class, known for its effects as a empathogen-entactogen, stimulant, and psychedelic. It is more commonly known by its street names, Ecstasy or Molly.

History[edit | edit source]

MDMAT was first synthesized in 1912 by the pharmaceutical company Merck. It was initially patented for use as an appetite suppressant, but this application was never marketed. The drug gained significant popularity in the 1980s and 1990s as a component in the rave and clubbing scenes.

Pharmacology[edit | edit source]

MDMAT works primarily by increasing the activity of three neurotransmitters in the brain: serotonin, dopamine, and norepinephrine. It achieves this by inhibiting their reuptake and promoting their release, leading to an overall increase in the concentrations of these neurotransmitters.

Effects[edit | edit source]

The effects of MDMAT can vary widely depending on the dose, the user's individual physiology, and the environment in which it's taken. Common effects include feelings of euphoria, increased sociability, heightened sensory perception, and increased energy. However, it can also cause a range of negative side effects, including dehydration, hyperthermia, bruxism, and in rare cases, severe neurological damage.

Legal Status[edit | edit source]

MDMAT is classified as a Schedule I drug under the United Nations Convention on Psychotropic Substances, meaning it is considered to have a high potential for abuse and no accepted medical use. However, some research suggests that it may have potential therapeutic uses in the treatment of post-traumatic stress disorder and other mental health conditions.